Compare Kyndryl Holdings Inc (KD) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kyndryl Holdings Inc vs Zoetis Inc — how do they compare? Kyndryl Holdings Inc trades at $13.43 (market cap $2.91B), while Zoetis Inc trades at $73.66 (market cap $31.14B). The key difference: Zoetis Inc is far larger — about 10.7× Kyndryl Holdings Inc's market cap, and Zoetis Inc pays a 2.81% dividend while Kyndryl Holdings Inc pays none. Which is the better fit depends on your goals.
| KD | ZTS | |
|---|---|---|
Market Cap | $2.91B | $31.14B |
Sector | Technology | Health |
52-Week High | $33.14 | $156.76 |
52-Week Low | $10.59 | $71.91 |
Enterprise Value | $5.74B | $38.70B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kyndryl (KD) trades at $13.025, down 4.44% on the day, with a neutral technical signal. The company reported a net loss in Q1 2027, missing revenue estimates, but maintains a strong cash flow position with $942M from operations in 2025. Recent news highlights strategic acquisitions and AI service expansions, while an ongoing legal investigation introduces uncertainty. The stock's valuation shows a high P/E of 36.11 but attractive EV/EBITDA of 4.04, with analyst consensus leaning hold.
The outlook is mixed: positive cash flow and strategic moves in AI modernization offer growth potential, but recent earnings misses and legal scrutiny pose risks. Investors should weigh the company's turnaround progress against execution challenges and market sentiment.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
